the Real World Study of Orelabrutinib in the Treatment of CLL/SLL
NCT05975164 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2023-08-03
Summary
This is a Multicenter, Retrospective Real-world Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China
Conditions
- CLL/SLL
Sponsors & Collaborators
-
Shandong University
lead OTHER
Principal Investigators
-
Chunyan Ji, Dr. · Qilu Hospital of Shandong University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-07-25
- Primary Completion
- 2023-12-10
- Completion
- 2024-07-10
More Related Trials
-
The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
NCT06557304 ·Status: NOT_YET_RECRUITING
-
Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice
NCT04094051 ·Status: UNKNOWN
-
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
NCT03932331 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
NCT05322733 ·Status: RECRUITING ·Phase: PHASE2
-
Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their Effectiveness
NCT03881592 ·Status: UNKNOWN
-
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
NCT00751296 ·Status: TERMINATED ·Phase: PHASE2
-
A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy
NCT06476899 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT03206918 ·Status: COMPLETED ·Phase: PHASE2
-
Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
NCT05665374 ·Status: COMPLETED
-
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05057494 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
NCT03425591 ·Status: COMPLETED
-
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
NCT05950997 ·Status: RECRUITING ·Phase: NA
-
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
NCT01419691 ·Status: COMPLETED ·Phase: PHASE2
-
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
NCT06378138 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
NCT05557695 ·Status: RECRUITING
-
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
NCT05959694 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia
NCT00036257 ·Status: COMPLETED ·Phase: PHASE1
-
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT03516617 ·Status: RECRUITING ·Phase: PHASE2
-
Real-world Study of Acalabrutinib
NCT06767891 ·Status: ENROLLING_BY_INVITATION
-
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia
NCT01161511 ·Status: COMPLETED ·Phase: PHASE1
-
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
NCT02315768 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
NCT06697184 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
New-diagnosed PCNSL Treated With Methotrexate (MTX) and Orelabrutinib-based Regimen
NCT06115824 ·Status: COMPLETED
-
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02556346 ·Status: WITHDRAWN ·Phase: PHASE1